Literature DB >> 23212108

Emerging target-based paradigms to prevent and treat migraine.

S D Silberstein1.   

Abstract

Migraine is a primary brain disorder resulting from altered modulation of normal sensory stimuli and trigeminal nerve dysfunction. The second edition of the International Classification of Headache Disorders (ICHD-2) defines seven subtypes of migraine. Migraine treatment can be acute or preventive. New targeted therapies include 5-HT(1F) receptor agonists, calcitonin gene-related peptide (CGRP) antagonists, nitric oxide synthetase inhibitors, and ion channel antagonists. A recent development is the creation of antibodies to CGRP and its receptor for migraine prevention.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23212108     DOI： 10.1038/clpt.2012.198

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  19 in total

Review 1.  Therapeutic antibodies against CGRP or its receptor.

Authors:  Marcelo E Bigal; Sarah Walter; Alan M Rapoport
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

Review 2.  Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.

Authors:  Marcelo E Bigal; Sarah Walter
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 3.  TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine.

Authors:  Sarah Walter; Marcelo E Bigal
Journal:  Curr Pain Headache Rep       Date:  2015-03

Review 4.  From LBR-101 to Fremanezumab for Migraine.

Authors:  Marcelo E Bigal; Alan M Rapoport; Stephen D Silberstein; Sarah Walter; Richard J Hargreaves; Ernesto Aycardi
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 5.  Prophylactic Treatment of Migraine.

Authors:  Azize Esra Gürsoy; Mustafa Ertaş
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 6.  Serotonin and sensory nerves: meeting in the cardiovascular system.

Authors:  Stephanie W Watts
Journal:  Vascul Pharmacol       Date:  2014-08-30       Impact factor: 5.773

Review 7.  Targeting CGRP: A New Era for Migraine Treatment.

Authors:  Stephanie Wrobel Goldberg; Stephen David Silberstein
Journal:  CNS Drugs       Date:  2015-06       Impact factor: 5.749

Review 8.  Emerging targets in migraine.

Authors:  Jan Hoffmann; Peter J Goadsby
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 9.  Anti-CGRP monoclonal antibodies in migraine: current perspectives.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Martina Curto; Andrea Negro; Raffaele Costantini; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2016-06-23       Impact factor: 3.397

Review 10.  Closing remarks: what future prospects can we expect in migraine management?

Authors:  R A Purdy
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.